Companies ›Healthcare ›HALE.NS

HALE.NS — NSE (India) Pharmaceuticals

Haleos Labs Ltd

$1 599,80

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

0,09 %

Op margin

8,4 %

ROE

3,3 %

Net margin

6,6 %

Debt / equity

0,57

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Haleos Labs Ltd maintains a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium, with a current ratio of 1.07, suggesting it has just enough current assets to cover its current liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Haleos reports a return on equity (ROE) of 3.34% and a return on assets (ROA) of 1.51%. These figures are below the industry median for ROE and ROA in the pharmaceutical sector, indicating that the company is underperforming its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the pharmaceutical industry where regulatory and demand shifts can be abrupt. Looking ahead, Haleos is projected to experience modest revenue growth, with a capital expenditure of -208.68 million INR in the latest period. This negative capex suggests a r

Business. Haleos Labs Ltd (HALE.NS) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

3,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning HALE.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to HALE.NS. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Haleos Labs Ltd (HALE.NS) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

In terms of profitability, Haleos reports a return on equity (ROE) of 3.34% and a return on assets (ROA) of 1.51%. These figures are below the industry median for ROE and ROA in the pharmaceutical sector, indicating that the company is underperforming its peers in terms of capital efficiency and asset utilization.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the pharmaceutical industry where regulatory and demand shifts can be abrupt.

Looking ahead, Haleos is projected to experience modest revenue growth, with a capital expenditure of -208.68 million INR in the latest period. This negative capex suggests a reduction in investment in long-term assets, which may impact future growth potential.

The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The risk assessment highlights the negative net cash position as a key flag, which could necessitate additional financing in the near term. No significant dilution sources have been identified in the latest filings, and the dilution potential remains low.

Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's focus appears to remain on maintaining its current product portfolio and managing its debt obligations.

Key takeaways

Haleos Labs Ltd has a moderate debt-to-equity ratio but faces liquidity constraints due to a negative net cash position.
The company's ROE and ROA are below industry medians, indicating underperformance in capital efficiency and asset utilization.
Revenue is concentrated in a single segment with no geographic diversification, increasing exposure to market-specific risks.
The company is projected to reduce capital expenditures, which may affect long-term growth potential.
The risk profile is characterized by medium liquidity risk and low dilution risk, with no significant dilution sources identified.

Bull / Bear case

Generated · model-assisted

BULL CASE · 3

Net income surged 121.2% year-over-year to INR 201 million, demonstrating strong bottom-line growth momentum.

Free cash flow turned positive at INR 179 million, marking a dramatic 32,227% improvement from the prior year.

Cash conversion ratio of 4.12 is best-in-class compared to the cohort median of 0.95, highlighting strong cash generation.

BEAR CASE · 3

Debt-to-equity ratio of 0.57 is well below the cohort median of 0.18, signaling higher financial leverage risk.

The company faces high credit risk, posing a significant threat to its financial stability and borrowing costs.

Medium liquidity risk suggests potential challenges in meeting short-term obligations or managing cash flow volatility.

In focus — financials by report

Valuation FY

Market price

$1 599,80

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$1.77B

Net cashⓘ

-$998.0M

Current ratioⓘ

1.1

Debt / equityⓘ

0.6

ROAⓘ

1.5%

ROEⓘ

3.3%

Cash conversionⓘ

412.0%

CapEx / revenueⓘ

-23.2%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin8,4 %Above median

Net Margin6,6 %Above median

ROE3,3 %Above median

Capex / Rev-23,2 %Bottom quartile

D/E0,57Below median

Cash Conv4,12Best in class

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Haleos Labs Ltd Market data — financials · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

HALE.NSCanonical

NSE (India) · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread